Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

breakingnow_w51jcqOctober 10, 2022

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Read the original article

Previous PostMichigan coach Mike Hart back in Ann Arbor, eyes return to team
Next PostCan the U.S. avoid recession? The Fed still thinks so, but Wall Street is very skeptical